Successful Treatment of Severe Psoriasis Relapse With Secukinumab(IL17 a Inhibitor) After Abrupt Brodalumab (IL17 Receptor Inhibitor) Discontinuation: A Retrospective Study Evaluating Long Term Efficacy and Safety
Journal of the American Academy of Dermatology - United States
doi 10.1016/j.jaad.2018.03.027
Full Text
Open PDFAbstract
Available in full text
Categories
Date
October 1, 2018
Authors
Publisher
Elsevier BV